Northern Trust Corp Adma Biologics, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 2,575,075 shares of ADMA stock, worth $42.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,575,075

Previous 2,429,688 5.98%

Holding current value

$42.8 Million

Previous $48.6 Million 9.07%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$15.62 - $22.62 $2.27 Million - $3.29 Million	145,387 Added 5.98%	2,575,075 $44.2 Million
Q3 2024 Nov 13, 2024	BUY	$11.21 - $20.03 $3.99 Million - $7.13 Million	355,919 Added 17.16%	2,429,688 $48.6 Million
Q2 2024 Aug 14, 2024	SELL	$5.98 - $11.18 $232,586 - $434,834	-38,894 Reduced 1.84%	2,073,769 $23.2 Million
Q1 2024 May 14, 2024	SELL	$4.4 - $6.74 $375,632 - $575,400	-85,371 Reduced 3.88%	2,112,663 $13.9 Million
Q4 2023 Feb 13, 2024	BUY	$3.08 - $4.52 $49,529 - $72,686	16,081 Added 0.74%	2,198,034 $9.94 Million
Q3 2023 Nov 13, 2023	BUY	$3.47 - $4.61 $61,089 - $81,159	17,605 Added 0.81%	2,181,953 $7.81 Million
Q2 2023 Aug 11, 2023	BUY	$3.12 - $4.22 $992,730 - $1.34 Million	318,183 Added 17.23%	2,164,348 $7.99 Million
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $576,219 - $740,853	191,435 Added 11.57%	1,846,165 $6.11 Million
Q4 2022 Feb 13, 2023	BUY	$2.47 - $3.88 $174,070 - $273,439	70,474 Added 4.45%	1,654,730 $6.42 Million
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $38,653 - $54,457	-19,041 Reduced 1.19%	1,584,256 $3.85 Million
Q2 2022 Aug 12, 2022	BUY	$1.43 - $2.2 $1.77 Million - $2.73 Million	1,239,043 Added 340.16%	1,603,297 $3.17 Million
Q1 2022 May 13, 2022	SELL	$1.28 - $1.83 $1,479 - $2,115	-1,156 Reduced 0.32%	364,254 $667,000
Q4 2021 Feb 08, 2022	BUY	$1.09 - $1.66 $92,650 - $141,100	85,000 Added 30.31%	365,410 $516,000
Q3 2021 Nov 15, 2021	SELL	$1.13 - $1.65 $17,791 - $25,979	-15,745 Reduced 5.32%	280,410 $317,000
Q2 2021 Aug 13, 2021	SELL	$1.51 - $2.07 $750,214 - $1.03 Million	-496,831 Reduced 62.65%	296,155 $474,000
Q1 2021 May 12, 2021	SELL	$1.67 - $2.95 $95,503 - $168,704	-57,188 Reduced 6.73%	792,986 $1.4 Million
Q4 2020 Feb 11, 2021	BUY	$1.8 - $2.56 $27,631 - $39,298	15,351 Added 1.84%	850,174 $1.66 Million
Q3 2020 Nov 16, 2020	SELL	$2.04 - $3.74 $15,650 - $28,693	-7,672 Reduced 0.91%	834,823 $2 Million
Q2 2020 Aug 14, 2020	SELL	$2.42 - $3.29 $30,293 - $41,184	-12,518 Reduced 1.46%	842,495 $2.47 Million
Q1 2020 May 14, 2020	BUY	$1.5 - $4.59 $309,643 - $947,509	206,429 Added 31.83%	855,013 $2.46 Million
Q4 2019 Feb 14, 2020	BUY	$3.89 - $5.15 $48,169 - $63,772	12,383 Added 1.95%	648,584 $2.59 Million
Q3 2019 Nov 13, 2019	BUY	$3.19 - $5.39 $1.07 Million - $1.82 Million	336,953 Added 112.6%	636,201 $2.83 Million
Q2 2019 Aug 13, 2019	BUY	$3.52 - $5.24 $132,623 - $197,427	37,677 Added 14.4%	299,248 $1.16 Million
Q1 2019 May 13, 2019	BUY	$2.61 - $4.35 $68,032 - $113,387	26,066 Added 11.07%	261,571 $991,000
Q4 2018 Feb 12, 2019	SELL	$2.17 - $6.12 $1,093 - $3,084	-504 Reduced 0.21%	235,505 $563,000
Q3 2018 Nov 14, 2018	BUY	$4.39 - $6.85 $117,195 - $182,867	26,696 Added 12.75%	236,009 $1.47 Million
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $790,946 - $980,124	180,170 Added 618.23%	209,313 $944,000
Q1 2018 May 09, 2018	SELL	$3.21 - $5.21 $7,261 - $11,785	-2,262 Reduced 7.2%	29,143 $134,000
Q4 2017 Feb 14, 2018	BUY	$2.06 - $3.24 $42,951 - $67,554	20,850 Added 197.54%	31,405 $101,000
Q3 2017 Nov 13, 2017	BUY	$2.76 - $3.71 $29,131 - $39,159	10,555	10,555 $33,000

Others Institutions Holding ADMA

# of Institutions

339

Shares Held

182M

Call Options Held

1.72M

Put Options Held

846K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.26B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Adma Biologics, Inc. Transaction History